FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, today announced the appointment of Eric Bjerkholt as chief financial officer.
“Eric is an accomplished CFO bringing an outstanding track record in driving financial performance, business development, and operations management,” said Chris Peetz, president and chief executive officer at Mirum. “Eric is joining at an important period of growth and global scale for Mirum, and it is a pleasure to have his experience and leadership at Mirum as we continue to execute on numerous initiatives across our rare disease franchises.”
Mr. Bjerkholt brings extensive business leadership experience from roles served in the biopharmaceutical industry. He comes to Mirum from Chinook Therapeutics, Inc., where he served as CFO overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions. Prior to Chinook, he served as CFO at Aimmune Therapeutics, Inc. Before Aimmune, Eric worked at Sunesis Pharmaceuticals, Inc., IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC. Prior to joining industry, Mr. Bjerkholt spent nearly a decade in healthcare investment banking at J.P. Morgan & Company, Inc. He is currently a member of the board of directors of CalciMedica, Inc., Cerus Corporation and Surrozen, Inc. Mr. Bjerkholt holds an MBA from Harvard Business School and a Cand.Oecon degree from the University of Oslo in Norway.
“Mirum is an exciting company that has achieved significant success in a short period of time,” said Mr. Bjerkholt. I am impressed by the company’s patient focus, scientific rigor, and vibrant culture, all critical elements in building a lasting and successful organization. I believe Mirum is poised for much continued success, and I look forward to helping the company grow and reach as many patients as possible around the world with solutions that address their medical needs.”
In conjunction with his appointment, the Compensation Committee of Mirum’s Board of Directors approved an inducement grant 110,000 shares of common stock, which will have an exercise price per share equal Mirum’s stock closing trading price on September 11, 2023, and 55,000 restricted stock units under Mirum’s 2020 Inducement Plan. The Compensation Committee approved the awards as an inducement material to Mr. Bjerkholt’s employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to Mr. Bjerkholt’s continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to his continued service relationship with Mirum through the applicable vesting dates.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).
